AI used to predict sequences within antibodies could lead to new therapeutic treatments
en-GBde-DEes-ESfr-FR

AI used to predict sequences within antibodies could lead to new therapeutic treatments


During this unique study, scientists sought to understand if artificial intelligence could be used to predict how the interior of antibodies are assembled in the body. Antibodies, which are comprised of ‘heavy’ and ‘light’ protein chains, are produced by B cells within the immune system and protect against viruses and bacteria.

Franca Fraternali, Professor of Integrative Computational Biology at University College London, said:

“Until now, it was widely assumed that the pairing of heavy and light chains within antibodies occurred at random. Using Immunomatch, we show for the first time that this assembly is, in fact, highly specific. Understanding these pairing rules is crucial for predicting antibody stability and performance and opens the door to the rational design of more effective therapeutics.”

To learn more, scientists created ImmunoMatch, based on an antibody-specific language model, which was applied to heavy and light chain antibody sequences collected from millions of single human B cells. The AI model was able to identify and predict pairings of chains, giving scientists an invaluable insight into how antibodies are combined.

The team also showed that ImmunoMatch can accurately analyse antibody sequences from immune cells actively responding to disease, including those from haematological cancers and B cells within solid tumours. These insights could accelerate the rational design of new therapeutic antibodies.

Professor Deborah Dunn-Walters, Professor of Immunology, at the University of Surrey, said:

“Using AI has helped us discover that the combinations of ‘heavy’ and ‘light’ chains are not as random as we previously thought.

“This information enables us to learn the nature-derived rules governing how proteins are combined to create functional antibodies.

“Antibodies are the single largest class of modern therapeutics. Around a quarter of all newly approved therapeutics are monoclonal antibodies, so understanding how antibodies are made is critical for their effective design.”

This study was published in Nature Methods.
Journal: Nature Methods
DOI: 10.1038/s41592-025-02913-x
Authors: Professor Deborah Dunn-Walters and Professor Franca Fraternali
Paper title: ImmunoMatch learns and predicts cognate pairing of heavy and light immunoglobulin chains
Regions: Europe, United Kingdom
Keywords: Science, Life Sciences, Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement